Medartis Holding AG (MED) - Net Assets
Based on the latest financial reports, Medartis Holding AG (MED) has net assets worth CHF261.20 Million CHF (≈ $330.23 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF465.70 Million ≈ $588.77 Million USD) and total liabilities (CHF204.50 Million ≈ $258.54 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check MED cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CHF261.20 Million |
| % of Total Assets | 56.09% |
| Annual Growth Rate | N/A |
| 5-Year Change | 26.57% |
| 10-Year Change | N/A |
| Growth Volatility | 389.52 |
Medartis Holding AG - Net Assets Trend (2014–2024)
This chart illustrates how Medartis Holding AG's net assets have evolved over time, based on quarterly financial data. Also explore Medartis Holding AG balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Medartis Holding AG (2014–2024)
The table below shows the annual net assets of Medartis Holding AG from 2014 to 2024. For live valuation and market cap data, see MED company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CHF269.65 Million ≈ $340.91 Million |
+5.76% |
| 2023-12-31 | CHF254.96 Million ≈ $322.34 Million |
+7.23% |
| 2022-12-31 | CHF237.78 Million ≈ $300.62 Million |
+6.15% |
| 2021-12-31 | CHF224.00 Million ≈ $283.19 Million |
+5.14% |
| 2020-12-31 | CHF213.04 Million ≈ $269.33 Million |
-1.18% |
| 2019-12-31 | CHF215.57 Million ≈ $272.54 Million |
-1.22% |
| 2018-12-31 | CHF218.23 Million ≈ $275.91 Million |
+1180.84% |
| 2017-12-31 | CHF17.04 Million ≈ $21.54 Million |
-0.39% |
| 2016-12-31 | CHF17.10 Million ≈ $21.62 Million |
+136.43% |
| 2015-12-31 | CHF-46.95 Million ≈ $-59.36 Million |
+13.47% |
| 2014-12-31 | CHF-54.26 Million ≈ $-68.60 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Medartis Holding AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3613660400.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CHF2.72 Million | 1.01% |
| Other Comprehensive Income | CHF286.46 Million | 106.24% |
| Total Equity | CHF269.65 Million | 100.00% |
Medartis Holding AG Competitors by Market Cap
The table below lists competitors of Medartis Holding AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ami Organics Limited
NSE:AMIORG
|
$1.18 Billion |
|
Ramsay Generale De Sante
PA:GDS
|
$1.18 Billion |
|
Winall Hi tech Seed
SHE:300087
|
$1.18 Billion |
|
Luye Pharma Group Ltd
F:LUP
|
$1.18 Billion |
|
El Puerto de Liverpool S.A.B. de C.V
MX:LIVEPOLC-1
|
$1.17 Billion |
|
China Railway Tielong Container Logistics Co Ltd
SHG:600125
|
$1.17 Billion |
|
CAP S.A
SN:CAP
|
$1.17 Billion |
|
CompuGroup Medical SE & Co. KGaA
XETRA:COP
|
$1.17 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medartis Holding AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 254,959,000 to 269,646,000, a change of 14,687,000 (5.8%).
- Net income of 3,528,000 contributed positively to equity growth.
- New share issuances of 629,000 increased equity.
- Other comprehensive income increased equity by 3,136,000.
- Other factors increased equity by 7,394,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CHF3.53 Million | +1.31% |
| Share Issuances | CHF629.00K | +0.23% |
| Other Comprehensive Income | CHF3.14 Million | +1.16% |
| Other Changes | CHF7.39 Million | +2.74% |
| Total Change | CHF- | 5.76% |
Book Value vs Market Value Analysis
This analysis compares Medartis Holding AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.54x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | CHF-4.00 | CHF76.90 | x |
| 2016-12-31 | CHF1.46 | CHF76.90 | x |
| 2017-12-31 | CHF1.45 | CHF76.90 | x |
| 2018-12-31 | CHF20.53 | CHF76.90 | x |
| 2019-12-31 | CHF18.36 | CHF76.90 | x |
| 2020-12-31 | CHF18.10 | CHF76.90 | x |
| 2021-12-31 | CHF18.98 | CHF76.90 | x |
| 2022-12-31 | CHF20.09 | CHF76.90 | x |
| 2023-12-31 | CHF20.84 | CHF76.90 | x |
| 2024-12-31 | CHF21.74 | CHF76.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medartis Holding AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.31%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.57%
- • Asset Turnover: 0.49x
- • Equity Multiplier: 1.71x
- Recent ROE (1.31%) is below the historical average (2.91%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | 8.83% | 0.80x | 0.00x | CHF11.97 Million |
| 2016 | 19.38% | 3.58% | 0.80x | 6.74x | CHF1.60 Million |
| 2017 | 5.09% | 0.82% | 0.80x | 7.66x | CHF-837.31K |
| 2018 | 1.93% | 3.46% | 0.47x | 1.17x | CHF-17.62 Million |
| 2019 | 1.00% | 1.65% | 0.45x | 1.34x | CHF-19.41 Million |
| 2020 | -0.44% | -0.74% | 0.45x | 1.33x | CHF-22.25 Million |
| 2021 | 3.05% | 4.28% | 0.54x | 1.33x | CHF-15.56 Million |
| 2022 | -2.43% | -3.16% | 0.56x | 1.38x | CHF-29.56 Million |
| 2023 | 0.24% | 0.29% | 0.61x | 1.37x | CHF-24.88 Million |
| 2024 | 1.31% | 1.57% | 0.49x | 1.71x | CHF-23.44 Million |
Industry Comparison
This section compares Medartis Holding AG's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $233,379,333
- Average return on equity (ROE) among peers: -91.71%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medartis Holding AG (MED) | CHF261.20 Million | 0.00% | 0.78x | $1.17 Billion |
| Kuros Biosciences AG (KURN) | $8.24 Million | -301.25% | 7.34x | $988.78 Million |
| Medacta Group SA (MOVE) | $330.04 Million | 14.35% | 1.11x | $3.06 Billion |
| Sonova H Ag (SOON) | $361.86 Million | 11.78% | 1.05x | $10.75 Billion |
About Medartis Holding AG
Medartis Holding AG, a medical device company, engages in the development, manufacturing, and sales of implant solutions worldwide. The company's medical devices are used for the treatment of surgical fixation of bone fractures for upper and lower extremities, as well as for the cranio-maxillofacial surgery. It provides osteosynthesis products for the hand, wrist, forearm, elbow, shoulder, and fo… Read more